AXSM insider sale notice: 20,000 shares proposed; August trades total 56,694 shares

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. (AXSM) Form 144 notice shows a proposed sale of 20,000 common shares to be executed on 08/28/2025 through Charles Schwab & Co., Inc., with an aggregate market value of $2,432,004.00. The filing reports the filer acquired 14,648 shares on 03/29/2017 and 5,352 shares on 03/19/2019 via exercise and paid cash. It also discloses recent sales by the same person totaling 56,694 shares during August 2025, generating gross proceeds of $6,851,308.00 across sales on 08/22/2025, 08/26/2025, and 08/27/2025. The filing includes a representation that the seller is not aware of undisclosed material adverse information.

Positive

• Disclosure of acquisition details: acquisition dates and payment method (cash) are provided for the shares being sold.
• Complete recent-sales reporting: the filing lists three August 2025 sales totaling 56,694 shares with gross proceeds specified for each sale.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sale disclosure; recent August sales total ~56.7k shares with modest market impact relative to float.

The Form 144 documents proposed and recent sales by an individual associated with Axsome Therapeutics. The proposed 20,000-share sale on 08/28/2025 is accompanied by details of acquisition (03/29/2017 and 03/19/2019 exercises) and cash payment, which supports clarity on cost basis. Recent reported disposals on 08/22, 08/26 and 08/27/2025 total 56,694 shares with combined gross proceeds of $6,851,308.00. Compared to the reported outstanding share count of 49,901,487, these transactions represent a small percentage of shares outstanding and are likely informational rather than market-moving.

Corporate Governance Expert

TL;DR: Filing is a standard Rule 144 disclosure showing compliance and signer attestation; no new governance actions reported.

The notice provides required compliance detail: broker name, amounts, acquisition dates, and payment method. The signer attests to lack of undisclosed material adverse information and references Rule 10b5-1 mechanics although no plan adoption date is provided. The document does not disclose any management changes, related-party transactions, or governance actions that would alter the companys corporate governance profile.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	20000	2432004.00	49901487	08/28/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/29/2017	Exercise and Hold	Axsome Therapeutics, Inc.			14648	03/29/2017	Cash
Common	03/19/2019	Exercise and Hold	Axsome Therapeutics, Inc.			5352	03/19/2019	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/22/2025	16694	2004598.00
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/26/2025	20000	2400658.00
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/27/2025	20000	2446052.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the AXSM Form 144 propose to sell?

The notice proposes sale of 20,000 common shares of Axsome Therapeutics on 08/28/2025 via Charles Schwab & Co., Inc.

How much is the aggregate market value of the proposed sale in the AXSM filing?

The filing lists an aggregate market value of $2,432,004.00 for the 20,000 shares proposed to be sold.

What acquisition history is disclosed for the shares being sold?

The filer reports acquiring 14,648 shares on 03/29/2017 and 5,352 shares on 03/19/2019 through exercise transactions, paid in cash.

Were there other recent sales by the same person disclosed?

Yes. Sales on 08/22/2025 (16,694 shares, $2,004,598.00), 08/26/2025 (20,000 shares, $2,400,658.00), and 08/27/2025 (20,000 shares, $2,446,052.00) are reported.

How large are these sales relative to outstanding shares?

The filing reports 49,901,487 shares outstanding; the 56,694 shares sold in August 2025 equal a small fraction of that total.